{"id":"full-amount-low-molecular-weight-heparin","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"1-3","effect":"Injection site hematoma"},{"rate":"1-2","effect":"Elevated transaminases"}]},"_chembl":{"chemblId":"CHEMBL4594468","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Low molecular weight heparin (LMWH) is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in smaller molecular fragments. These fragments bind to antithrombin III and potentiate its inhibition of factor Xa and thrombin (factor IIa), thereby preventing thrombus formation. LMWH has more predictable pharmacokinetics and bioavailability compared to unfractionated heparin, allowing for subcutaneous administration without routine monitoring.","oneSentence":"Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:53.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prophylaxis in surgical patients"},{"name":"Treatment of deep vein thrombosis"},{"name":"Treatment of pulmonary embolism"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT02658838","phase":"PHASE4","title":"The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2015-04","conditions":"LOVASTATIN/TICAGRELOR [VA Drug Interaction]","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Full amount enoxaparin"],"phase":"marketed","status":"active","brandName":"full amount low molecular weight heparin","genericName":"full amount low molecular weight heparin","companyName":"Beijing Anzhen Hospital","companyId":"beijing-anzhen-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa. Used for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}